Needham analyst Michael Matson has maintained their bullish stance on NEO stock, giving a Buy rating today.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Michael Matson has given his Buy rating due to a combination of factors, including NeoGenomics’ better‑than‑expected first‑quarter 2026 revenue and EBITDA performance and an upward revision to the company’s full‑year revenue outlook. He also notes that underlying organic growth is improving, with solid momentum in the Clinical segment and particularly strong expansion in next‑generation sequencing, even as Non‑Clinical revenue remains a headwind.
Matson highlights that profitability metrics are trending favorably, with EBITDA margins advancing year over year despite some pressure on gross margins. He further points to the launch of new liquid biopsy and minimal residual disease assays, supported by a growing salesforce, as incremental growth drivers, and he views the expectation of turning free‑cash‑flow positive in 2026 as a key de‑risking milestone, supporting his unchanged $15 price target and Buy recommendation.
According to TipRanks, Matson is an analyst with an average return of -0.8% and a 41.28% success rate. Matson covers the Healthcare sector, focusing on stocks such as Boston Scientific, Artivion, and Medtronic.
In another report released today, Leerink Partners also upgraded the stock to a Buy with a $25.00 price target.